Incruse Ellipta (Umeclidinium bromide) for COPD

Overview
Incruse Ellipta is a prescription drug approved by the Food and Drug Administration (FDA) for long-term, once-daily maintenance treatment of airflow obstruction in people with chronic obstructive pulmonary disease (COPD). Incruse Ellipta is also known by its drug name, Umeclidinium bromide.

Incruse Ellipta is an anticholinergic drug and a long-acting bronchodilator, or drug that dilates the bronchi and bronchioles in the lungs, making it easier to breathe. Incruse Ellipta is believed to work by relaxing smooth muscles in the airways.

How do I take it?
Incruse Ellipta is taken once daily.

Incruse Ellipta comes in the form of powder packaged in a foil blister strip. Incruse Ellipta is delivered with the special Ellipta inhaler.

Side effects
The FDA-approved label for Incruse Ellipta lists common side effects including cold symptoms, cough, upper respiratory infection, and joint pain.

Rare but serious side effects listed for Incruse Ellipta can include worsening of glaucoma or urinary retention, hypersensitivity reactions, and paradoxical bronchospasm (bronchospasm caused by medication).

For more details about this treatment, visit:

Incruse – GSK
http://www.incruse.com/